The American Academy of Pediatrics states it is "premature to recommend the administration of activated charcoal" as an alternative to ipecac syrup to treat ingestion of a potentially poisonous substance in a Nov. 3 1policy statement. Charcoal is "poorly accepted by young children" and does not store well in the home, the statement says. However, AAP adds that ipecac should "no longer be used routinely as a home treatment strategy" either. The use of activated charcoal in conjunction with ipecac syrup was discussed at Nonprescription Drugs Advisory Committee's June 2003 meeting on retaining ipecac's current OTC status (2"The Tan Sheet" June 2, 2003, p. 5)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.
